Submitted:
07 January 2024
Posted:
08 January 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Material and Methods
3. Results and Discussion
4. Conclusions
References
- Koizumi, M., Watanabe, T., Masumoto, J., Sunago, K., Imamura, Y., Kanemitsu, K., ... & Hiasa, Y. (2021). Apoptosis-associated speck-like protein containing a CARD regulates the growth of pancreatic ductal adenocarcinoma. Scientific Reports, 11(1), 22351. [CrossRef]
- Tang, X., Liu, X., Wang, Z., Chen, M., & Zhang, D. (2023). Molecular Characterization, Expression, and Regulatory Signal Pathway Analysis of Inflammasome Component Apoptosis-Associated Speck-like Protein Containing a CARD Domain (ASC) in Large Yellow Croaker (Larimichthys crocea). International Journal of Molecular Sciences, 24(3), 2175. [CrossRef]
- de Alba, E. (2009). Structure and interdomain dynamics of apoptosis-associated speck-like protein containing a CARD (ASC). Journal of Biological Chemistry, 284(47), 32932-32941. [CrossRef]
- Petrilli, V., Papin, S., & Tschopp, J. (2005). The inflammasome. Current Biology, 15(15), R581. 15.
- Man, S. M., & Kanneganti, T. D. (2015). Regulation of inflammasome activation. Immunological reviews, 265(1), 6-21. 1. [CrossRef]
- Seligman, B. (1962). Bromelain: An anti-inflammatory agent. Angiology, 13(11), 508-510. [CrossRef]
- Pavan, R., Jain, S., & Kumar, A. (2012). Properties and therapeutic application of bromelain: a review. Biotechnology research international, 2012. [CrossRef]
- Rathnavelu, V., Alitheen, N. B., Sohila, S., Kanagesan, S., & Ramesh, R. (2016). Potential role of bromelain in clinical and therapeutic applications. Biomedical reports, 5(3), 283-288. [CrossRef]
- Yan, Y., Tao, H., He, J., & Huang, S. Y. (2020). The HDOCK server for integrated protein–protein docking. Nature protocols, 15(5), 1829-1852. [CrossRef]
- Yan, Y., Zhang, D., Zhou, P., Li, B., & Huang, S. Y. (2017). HDOCK: a web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. Nucleic acids research, 45(W1), W365-W373. [CrossRef]

| Receptor (PDB ID: 6U7D-PDB Chain A ID:2KN6Chain A) |
Docking Score (kcal/mol) -208.89 |
Confidence Score 0.7646 |
Ligand rmsd(Å) 62.17 |
| VAL 95A 2.149 |
| ASP 96A 3.921 |
| ALA 99A 2.707 |
| ILE 104A 4.247 |
| TRP 106A 3.988 |
| ARG 107A 4.026 |
| ASP 108A 2.023 |
| TYR 109A 0.923 |
| GLY 110A 2.807 |
| ILE 136A 4.971 |
| TYR 137A 1.729 |
| LYS 138A 2.182 |
| ILE 139A 1.108 |
| LYS 140A 2.984 |
| LYS 141A 4.059 |
| GLY 142A 4.302 |
| LEU 144A 4.118 |
| ILE 174A 4.776 |
| LYS 177A 3.584 |
| ASN 201A 3.677 |
| SER 202A 3.068 |
| ALA 203A 3.243 |
| TYR 204A 3.012 |
| THR 206A 2.833 |
| GLY 207A 3.447 |
| TYR 208A 4.345 |
| TYR 221A 0.946 |
| SER 224A 3.491 |
| LYS 225A 2.326 |
| GLN 226A 3.104 |
| TYR 310A 2.250 |
| PRO 311A 3.689 |
| THR 12A 2.204 |
| LEU 313A 4.328 |
| GLU 314A 2.966 |
| SER 315A 2.853 |
| MET 1A 2.149 |
| GLY 2A 4.040 |
| ARG 3A 0.946 |
| ALA 4A 4.062 |
| ARG 33A 2.182 |
| GLU 34A 2.023 |
| TYR 36A 2.728 |
| TYR 60A 4.469 |
| LEU 61A 0.923 |
| GLU 62A 2.681 |
| THR 63A 2.326 |
| TYR 64A 3.020 |
| GLU 67A 1.108 |
| LEU 68A 5.000 |
| ASN 71A 3.297 |
| ARG 74A 4.048 |
| ALA 82A 4.754 |
| GLY 83A 3.277 |
| GLN 86A 2.853 |
| ALA 87A 4.392 |
| THR 89A 3.396 |
| HIS 90A 2.204 |
| GLN 91A 2.966 |
| GLY 92A 2.899 |
| SER 93A 3.447 |
| GLY 94A 2.833 |
| ALA 95A 3.422 |
| ALA 96A 4.451 |
| GLY 99A 3.584 |
| ILE 100A 3.054 |
| GLN 101A 3.012 |
| ALA 102A 3.909 |
| PRO 103A 1.729 |
| 95A - 1A 2.149 |
| 95A - 2A 4.040 |
| 96A - 1A 4.397 |
| 96A - 2A 4.167 |
| 96A - 3A 3.921 |
| 99A - 1A 2.707 |
| 99A - 62A 3.792 |
| 104A - 61A 4.247 |
| 106A - 63A 4.365 |
| 106A - 64A 4.076 |
| 106A - 67A 3.988 |
| 107A - 34A 4.026 |
| 108A - 34A 2.023 |
| 108A - 36A 2.728 |
| 109A - 33A 4.188 |
| 109A - 34A 4.144 |
| 109A - 36A 3.403 |
| 109A - 60A 4.469 |
| 109A - 61A 0.923 |
| 109A - 64A 3.020 |
| 110A - 33A 2.807 |
| 110A - 34A 4.173 |
| 136A - 67A 4.971 |
| 137A - 103A 1.729 |
| 138A - 33A 2.182 |
| 138A - 64A 4.683 |
| 139A - 63A 4.681 |
| 139A - 67A 1.108 |
| 139A - 68A 5.000 |
| 139A - 71A 4.808 |
| 140A - 67A 3.532 |
| 140A - 71A 3.297 |
| 140A - 74A 4.048 |
| 140A - 86A 2.984 |
| 140A - 89A 3.396 |
| 140A - 90A 4.614 |
| 141A - 71A 4.518 |
| 141A - 74A 4.059 |
| 141A - 86A 4.584 |
| 142A - 33A 4.302 |
| 142A - 71A 4.416 |
| 144A - 33A 4.118 |
| 174A - 100A 4.776 |
| 177A - 99A 3.584 |
| 177A - 100A 3.687 |
| 201A - 103A 3.677 |
| 202A - 103A 3.068 |
| 203A - 103A 3.243 |
| 204A - 100A 3.054 |
| 204A - 101A 3.012 |
| 204A - 102A 3.909 |
| 204A - 103A 3.145 |
| 206A - 92A 4.127 |
| 206A - 93A 4.399 |
| 206A - 94A 2.833 |
| 206A - 95A 3.422 |
| 206A - 96A 4.451 |
| 207A - 93A 3.447 |
| 207A - 94A 4.592 |
| 207A - 95A 4.741 |
| 208A - 93A 4.345 |
| 221A - 3A 0.946 |
| 221A - 62A 4.666 |
| 224A - 63A 3.491 |
| 225A - 3A 2.779 |
| 225A - 4A 4.062 |
| 225A - 62A 2.681 |
| 225A - 63A 2.326 |
| 225A - 67A 4.109 |
| 225A - 89A 3.650 |
| 226A - 90A 3.104 |
| 310A - 90A 2.250 |
| 311A - 90A 3.689 |
| 312A - 90A 2.204 |
| 312A - 91A 4.804 |
| 312A - 92A 2.899 |
| 312A - 93A 4.147 |
| 313A - 86A 4.328 |
| 313A - 90A 4.368 |
| 313A - 92A 4.823 |
| 314A - 87A 4.392 |
| 314A - 90A 4.473 |
| 314A - 91A 2.966 |
| 314A - 92A 4.093 |
| 314A - 95A 4.088 |
| 315A - 74A 4.883 |
| 315A - 82A 4.754 |
| 315A - 83A 3.277 |
| 315A - 86A 2.853 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
